Effects of tegaserod and erythromycin in upper gut dysmotility

A comparative study

Issam Nasr, Satish Sanku Chander Rao, Ashok Attaluri, Syed M.A. Hashmi, Robert Summers

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. We prospectively assessed and compared the effects of tegaserod and erythromycin on upper gut motility. Methods In an open label, non-crossover study, 22 patients (M/F=4/18; mean age=37 years) with symptoms of upper gut dysmotility underwent 24-hour ambulatory antroduodenojejunal manometry with a six-sensor solid state probe. The effects of 12 mg oral tegaserod were compared with 125 mg intravenous erythromycin by quantifying pressure wave activity and assessing motor patterns. Results Motor activity increased (p<0.05) in antrum, duodenum and jejunum with both drugs when compared to baseline period. The motor response with tegaserod was higher (p<0.05) in jejunum and occurred during the second or third hours, whereas with erythromycin, it was higher (p<0.05) in antrum and occurred within 30 minutes. After tegaserod, a 'fed-response' like pattern was seen whereas after erythromycin, large amplitude (>100 mmHg) antral contractions at 3 cycles per minute were seen. Following tegaserod and erythromycin, phase III MMCs occurred in 12 (55%) and 8 (36%) patients respectively (p>0.05). Conclusions Both drugs increase upper gut motility and induce MMC's, but exert a differential response. Tegaserod produces a more sustained prokinetic effect in the duodenum/ jejunum, whereas erythromycin predominantly increases antral motor activity.

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalIndian Journal of Gastroenterology
Volume28
Issue number4
DOIs
StatePublished - Nov 24 2009
Externally publishedYes

Fingerprint

Erythromycin
Motor Activity
Manometry
Jejunum
Duodenum
tegaserod
Pressure
Pharmaceutical Preparations
Antral

Keywords

  • Dysmotility
  • Erythromycin
  • Small bowel manometry
  • Tegaserod

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effects of tegaserod and erythromycin in upper gut dysmotility : A comparative study. / Nasr, Issam; Rao, Satish Sanku Chander; Attaluri, Ashok; Hashmi, Syed M.A.; Summers, Robert.

In: Indian Journal of Gastroenterology, Vol. 28, No. 4, 24.11.2009, p. 136-142.

Research output: Contribution to journalArticle

Nasr, Issam ; Rao, Satish Sanku Chander ; Attaluri, Ashok ; Hashmi, Syed M.A. ; Summers, Robert. / Effects of tegaserod and erythromycin in upper gut dysmotility : A comparative study. In: Indian Journal of Gastroenterology. 2009 ; Vol. 28, No. 4. pp. 136-142.
@article{9d2f1ba18cde4eebac66a348c8b37ea5,
title = "Effects of tegaserod and erythromycin in upper gut dysmotility: A comparative study",
abstract = "Objectives Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. We prospectively assessed and compared the effects of tegaserod and erythromycin on upper gut motility. Methods In an open label, non-crossover study, 22 patients (M/F=4/18; mean age=37 years) with symptoms of upper gut dysmotility underwent 24-hour ambulatory antroduodenojejunal manometry with a six-sensor solid state probe. The effects of 12 mg oral tegaserod were compared with 125 mg intravenous erythromycin by quantifying pressure wave activity and assessing motor patterns. Results Motor activity increased (p<0.05) in antrum, duodenum and jejunum with both drugs when compared to baseline period. The motor response with tegaserod was higher (p<0.05) in jejunum and occurred during the second or third hours, whereas with erythromycin, it was higher (p<0.05) in antrum and occurred within 30 minutes. After tegaserod, a 'fed-response' like pattern was seen whereas after erythromycin, large amplitude (>100 mmHg) antral contractions at 3 cycles per minute were seen. Following tegaserod and erythromycin, phase III MMCs occurred in 12 (55{\%}) and 8 (36{\%}) patients respectively (p>0.05). Conclusions Both drugs increase upper gut motility and induce MMC's, but exert a differential response. Tegaserod produces a more sustained prokinetic effect in the duodenum/ jejunum, whereas erythromycin predominantly increases antral motor activity.",
keywords = "Dysmotility, Erythromycin, Small bowel manometry, Tegaserod",
author = "Issam Nasr and Rao, {Satish Sanku Chander} and Ashok Attaluri and Hashmi, {Syed M.A.} and Robert Summers",
year = "2009",
month = "11",
day = "24",
doi = "10.1007/s12664-009-0048-6",
language = "English (US)",
volume = "28",
pages = "136--142",
journal = "Indian Journal of Gastroenterology",
issn = "0254-8860",
publisher = "Indian Society of Gastroenterology",
number = "4",

}

TY - JOUR

T1 - Effects of tegaserod and erythromycin in upper gut dysmotility

T2 - A comparative study

AU - Nasr, Issam

AU - Rao, Satish Sanku Chander

AU - Attaluri, Ashok

AU - Hashmi, Syed M.A.

AU - Summers, Robert

PY - 2009/11/24

Y1 - 2009/11/24

N2 - Objectives Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. We prospectively assessed and compared the effects of tegaserod and erythromycin on upper gut motility. Methods In an open label, non-crossover study, 22 patients (M/F=4/18; mean age=37 years) with symptoms of upper gut dysmotility underwent 24-hour ambulatory antroduodenojejunal manometry with a six-sensor solid state probe. The effects of 12 mg oral tegaserod were compared with 125 mg intravenous erythromycin by quantifying pressure wave activity and assessing motor patterns. Results Motor activity increased (p<0.05) in antrum, duodenum and jejunum with both drugs when compared to baseline period. The motor response with tegaserod was higher (p<0.05) in jejunum and occurred during the second or third hours, whereas with erythromycin, it was higher (p<0.05) in antrum and occurred within 30 minutes. After tegaserod, a 'fed-response' like pattern was seen whereas after erythromycin, large amplitude (>100 mmHg) antral contractions at 3 cycles per minute were seen. Following tegaserod and erythromycin, phase III MMCs occurred in 12 (55%) and 8 (36%) patients respectively (p>0.05). Conclusions Both drugs increase upper gut motility and induce MMC's, but exert a differential response. Tegaserod produces a more sustained prokinetic effect in the duodenum/ jejunum, whereas erythromycin predominantly increases antral motor activity.

AB - Objectives Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. We prospectively assessed and compared the effects of tegaserod and erythromycin on upper gut motility. Methods In an open label, non-crossover study, 22 patients (M/F=4/18; mean age=37 years) with symptoms of upper gut dysmotility underwent 24-hour ambulatory antroduodenojejunal manometry with a six-sensor solid state probe. The effects of 12 mg oral tegaserod were compared with 125 mg intravenous erythromycin by quantifying pressure wave activity and assessing motor patterns. Results Motor activity increased (p<0.05) in antrum, duodenum and jejunum with both drugs when compared to baseline period. The motor response with tegaserod was higher (p<0.05) in jejunum and occurred during the second or third hours, whereas with erythromycin, it was higher (p<0.05) in antrum and occurred within 30 minutes. After tegaserod, a 'fed-response' like pattern was seen whereas after erythromycin, large amplitude (>100 mmHg) antral contractions at 3 cycles per minute were seen. Following tegaserod and erythromycin, phase III MMCs occurred in 12 (55%) and 8 (36%) patients respectively (p>0.05). Conclusions Both drugs increase upper gut motility and induce MMC's, but exert a differential response. Tegaserod produces a more sustained prokinetic effect in the duodenum/ jejunum, whereas erythromycin predominantly increases antral motor activity.

KW - Dysmotility

KW - Erythromycin

KW - Small bowel manometry

KW - Tegaserod

UR - http://www.scopus.com/inward/record.url?scp=77954673204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954673204&partnerID=8YFLogxK

U2 - 10.1007/s12664-009-0048-6

DO - 10.1007/s12664-009-0048-6

M3 - Article

VL - 28

SP - 136

EP - 142

JO - Indian Journal of Gastroenterology

JF - Indian Journal of Gastroenterology

SN - 0254-8860

IS - 4

ER -